Mandate

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.

The offering will provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs and provided that the over-allotment option is fully exercised. In connection with the offering, Cinclus Pharma also carries out a set-off issue at the offering price to convert outstanding bridge loans. 

Cinclus Pharma is a clinical-stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive GERD.

Vinge's team mainly consists of Dain Hård Nevonen,Amanda Knutsson, Anna Svensson,Michaela Ådén and Filip Magnusson (Capital Markets and Public M&A), Stojan Arnestål (IP/Life science), Maria Schultzberg (Corporate taxation), Mathilda Persson (Commercial agreements), Gulestan Ali (Compliance), Nicklas Thorgerzon (IT/GDPR), Jonatan Stentorp (Employment) and Sofia Haggren (Financing).

Related

Vinge advises Baseload Capital in connection with an investment from Google

Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025

Vinge advises Acrinova in connection with the sale of properties

Vinge advises Acrinova AB (publ) in connection with its sale of properties with an underlying property value of SEK 1.4 billion.
April 15, 2025

Vinge has advised Visa in connection with its investment in Mynt AB

Vinge has advised Visa in connection with its investment in the Swedish fintech company Mynt AB ("Mynt"). The investment, which is part of Mynt's announced Series B funding round, underscores Visa's commitment to supporting innovative fintech solutions and improving payment experiences for businesses across Europe.
April 14, 2025